# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-263542
Filing Date
2025-11-04
Accepted
2025-11-04 07:11:45
Documents
83
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | beam-20250930.htm iXBRL | 10-Q | 2967867
2 | EX-31.1 | beam-ex31_1.htm | EX-31.1 | 19594
3 | EX-31.2 | beam-ex31_2.htm | EX-31.2 | 29664
4 | EX-32.1 | beam-ex32_1.htm | EX-32.1 | 11737
5 | EX-32.2 | beam-ex32_2.htm | EX-32.2 | 10855
| Complete submission text file | 0001193125-25-263542.txt |  | 12105028

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | beam-20250930.xsd | EX-101.SCH | 1518630
86 | EXTRACTED XBRL INSTANCE DOCUMENT | beam-20250930_htm.xml | XML | 2508362

Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39208 | Film No.: 251446429
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)